KCNMB2 Inhibitors

Calcium-activated potassium channel, subfamily M subunit beta-2 (KCNMB2) inhibitors are a diverse group of chemical compounds that serve to decrease the functional activity of the KCNMB2 protein, a regulatory subunit of large conductance calcium-activated potassium (BK) channels. Compounds like Paxilline, Charybdotoxin, and Iberiotoxin are potent inhibitors of KCNMB2 activity, exerting their effects by directly binding to the BK channels and preventing the normal flow of potassium ions through the channel pore. This inhibition is crucial as it affects the physiological processes that depend on the proper functioning of these channels, such as smooth muscle tone regulation and neuronal excitability. Similarly, Tetraethylammonium (TEA) and Barium chloride also block these channels, though less selectively, yet still achieve a decrease in KCNMB2 activity by impeding potassium efflux.

Other inhibitors, including Penitrem A, Lolitrem B, and Rottlerin, are toxins that target the BK channels, diminishing KCNMB2's modulatory role and, consequently, its functional effects. Slotoxin, another peptide inhibitor, selectively suppresses BK channels with KCNMB2 subunits, further contributing to the overall inhibition of KCNMB2 activity. Additionally, compounds such as Dequalinium and Glibenclamide act on the channels with less specificity but still manage to inhibit the KCNMB2 subunit's contribution to channel function. Cymarin, though primarily affecting cardiac function through its interaction with Na+/K+-ATPase, also demonstrates the capacity to inhibit BK channels that incorporate KCNMB2, underscoring the broad potential for chemical inhibition of this protein. Collectively, these inhibitors operate through various mechanisms, yet they all converge on the common outcome of reducing KCNMB2-mediated activity, highlighting the intricate control of cellular processes by BK channel modulation.